- Home
- SHOT vs INKT Comparison
SHOT vs INKT Comparison
Compare SHOT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- INKT
- Stock Information
- Founded
- SHOT 2018
- INKT 2017
- Country
- SHOT United States
- INKT United States
- Employees
- SHOT N/A
- INKT N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- SHOT Health Care
- INKT Health Care
- Exchange
- SHOT Nasdaq
- INKT Nasdaq
- Market Cap
- SHOT 30.4M
- INKT 28.8M
- IPO Year
- SHOT 2020
- INKT 2021
- Fundamental
- Price
- SHOT $0.43
- INKT $62.86
- Analyst Decision
- SHOT
- INKT Strong Buy
- Analyst Count
- SHOT 0
- INKT 2
- Target Price
- SHOT N/A
- INKT $37.50
- AVG Volume (30 Days)
- SHOT 6.3M
- INKT 2.4M
- Earning Date
- SHOT 08-13-2025
- INKT 08-12-2025
- Dividend Yield
- SHOT N/A
- INKT N/A
- EPS Growth
- SHOT N/A
- INKT N/A
- EPS
- SHOT N/A
- INKT N/A
- Revenue
- SHOT $573,336.00
- INKT N/A
- Revenue This Year
- SHOT N/A
- INKT N/A
- Revenue Next Year
- SHOT N/A
- INKT N/A
- P/E Ratio
- SHOT N/A
- INKT N/A
- Revenue Growth
- SHOT 69.32
- INKT N/A
- 52 Week Low
- SHOT $0.23
- INKT $4.56
- 52 Week High
- SHOT $1.77
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- SHOT 54.76
- INKT 57.39
- Support Level
- SHOT $0.35
- INKT $6.80
- Resistance Level
- SHOT $0.48
- INKT $7.88
- Average True Range (ATR)
- SHOT 0.06
- INKT 0.40
- MACD
- SHOT 0.01
- INKT 0.02
- Stochastic Oscillator
- SHOT 46.94
- INKT 58.86
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.